JPH09255578A - Preparation for external use for treating infectious skin disease - Google Patents

Abstract

PROBLEM TO BE SOLVED: To obtain a preparation for external use capable of inhibiting the growth of infectious pathogens or killing the pathogens, capable of depressing inflammations and exhibiting high therapeutic effects by adding vitamin E and squalane to a medicine for infectious skin diseases. SOLUTION: This preparation contains (A) a medicine for infectious skin diseases preferably in an amount of 0.01-20wt.%, (B) vitamin E preferably in an amount of 0.1-99.5wt.% and (C) squalane preferably in an amount of 0.1-99.5wt.%. The preparation preferably further contains (D) one or more kinds of an N-acylsarcosine (salt), a higher fatty acid ester obtained by reacting a 10-18C higher fatty acid with a 1-20C alcohol, etc., as a percutaneous absorption-stimulating agent.

Description

Detailed Description of the Invention

[0001]

TECHNICAL FIELD The present invention relates to an external preparation for treating infectious skin diseases.

[0002]

2. Description of the Related Art Conventionally, infectious skin diseases such as bacteria have been mainly treated with antibiotics and synthetic antibacterial agents (JP-A-3-47122, JP-A-6-183946 and JP-A-6-183122). 72850, etc.). Further, a means for improving the percutaneous absorption of the drug and the skin residual property has been proposed for the purpose of enhancing the action of the antibacterial agent (JP-A-2-1).
80836, JP 6-183946 A, JP 6-72850 A, etc.). However, in the treatment of infectious skin diseases, it is extremely important not only to simply enhance the action of the antibacterial agent but also to suppress the excessive inflammatory reaction due to infection. Although external agents for corticosteroids are often used as anti-inflammatory agents, the application of corticosteroids rather enhances immunocompetence, thins the skin, and abnormally activates the pilosebaceous system. In addition to the potential side effects, transdermally absorbed corticosteroids have a systemic side effect risk. Therefore, it is desired to develop a safe and effective external preparation for infectious skin diseases and pathological conditions associated with inflammation.

[0003]

DISCLOSURE OF THE INVENTION The present invention is intended to solve the above-mentioned problems, and its purpose is to treat infectious skin diseases with extremely few side effects, enhanced anti-inflammatory action and high therapeutic effect. It is to provide an external preparation.

[0004]

[Means for Solving the Problems] In order to solve the above-mentioned problems, the present inventors have earnestly studied, and as a result, by adding vitamin E and squalane to an agent for infectious skin diseases, infectious pathogens (bacteria It was found that an external preparation for the treatment of infectious skin diseases, which has a high therapeutic effect, can be obtained by inhibiting the growth of () and killing the pathogen and suppressing inflammation.

The external preparation for treating infectious skin diseases according to claim 1 of the present invention (hereinafter referred to as the present invention 1) contains an agent for infectious skin diseases, vitamin E and squalane.

The external preparation for treating infectious skin diseases according to claim 2 of the present invention (hereinafter referred to as the present invention 2) contains 0.01 to 20% by weight of the agent for infectious skin diseases and vitamin E. Content is more than 0.1% by weight and 99.5% by weight or less, and squalane content is more than 0.1% by weight and 99.5% by weight.
The external preparation for treating infectious skin diseases according to claim 1, which is less than 1.

The above-mentioned agent for infectious skin diseases is a substance that inhibits the growth of infectious pathogens (for example, bacteria) or kills them, for example, erythromycin,
Chloramphenicol, oxytetracycline and its hydrochloride, tetracycline and its hydrochloride, demethylchlortetracycline and its hydrochloride, kanamycin and its sulfate, fradiomycin and its sulfate, gentamicin and its sulfate, polymyxin B and its Antibiotics such as sulfates, sodium fusidate, gramidine S hydrochloride, streptomycin and its sulfates, bacitracin, nadiflorisacin and its sulfates; sulfa drugs such as sulfadiazine and silver sulfadiazine. These can be used alone or in combination of two or more.

When the content of the agent for infectious skin diseases in the external preparation is small, the growth inhibitory or lethal effect of the infectious pathogen is insufficient, and when it is large, the effect is increased to some extent, but the appearance of resistant bacteria and contact Since side effects such as the development of dermatitis are likely to occur, it is preferably 0.01 to 20% by weight, though it varies depending on the type of infectious skin disease agent.
0.1 to 5% by weight is more preferable.

The above-mentioned vitamin E refers to tocopherol (vitamin E) and its derivatives, and those listed in the Japanese Pharmacopoeia include, for example, dl-α-tocopherol, tocopherol acetate (vitamin E acetate), amber. Acid tocopherol (vitamin E succinate) and the like can be mentioned. Examples not listed in the Japanese Pharmacopoeia include, for example, α-tocopherol, β-tocopherol, γ-tocopherol, δ-tocopherol, tocopherol nicotinate (vitamin E nicotinate), tocopherol phosphate (vitamin E phosphate) and the like. Is mentioned.

If the content of vitamin E in the external preparation decreases, the effect of suppressing inflammation becomes insufficient, and even if it increases, the effect of suppressing inflammation does not remarkably increase depending on the content. Since it may be difficult to maintain the dosage form, it is preferably more than 0.1% by weight and 99.5% by weight or less, more preferably 0.2 to 80% by weight, and 0.5 to
30% by weight is most preferred.

The above-mentioned squalane reduces squalene, which is an unsaturated hydrocarbon existing in liver oil of deep-sea fish, especially sharks, or vegetable oils such as olive oil, rice bran oil, wheat germ oil, sesame oil and cottonseed oil. It is a substance that is formed.

When the content of squalane in the external preparation decreases, the effect of suppressing inflammation becomes insufficient, and even if it increases, the effect of suppressing inflammation does not remarkably increase depending on the content. Since it may be difficult to hold the mold, it is preferably more than 0.1% by weight and less than 99.5% by weight, more preferably 0.5-80% by weight, and 10-3.
0% by weight is most preferred.

A particularly preferred combination of the content of each component in the external preparation is 0.1 to 5% by weight of the agent for infectious skin diseases,
Vitamin E 0.5-30% by weight and squalane 10-3
0% by weight.

The external preparation for treating infectious skin diseases according to claim 3 of the present invention (hereinafter referred to as the present invention 3) further comprises N-
Acyl sarcosine (salt), higher fatty acid ester which is a reaction product of higher fatty acid having 10 to 18 carbon atoms and alcohol having 1 to 20 carbon atoms, dicarboxylic acid (salt) having 2 to 10 carbon atoms, and 3 to 6 carbon atoms 1 or 2 containing at least one percutaneous absorption enhancer selected from the group consisting of a hydroxycarboxylic acid ester, which is a reaction product of a hydroxycarboxylic acid of 1) with an alcohol having 1 to 20 carbon atoms, and a fatty acid ethanolamide. The external preparation for the treatment of infectious skin diseases as described above.

Examples of the N-acyl sarcosine include N-lauroyl sarcosine, N-oleoyl sarcosine, N-palmitoyl sarcosine, coconut oil fatty acid sarcosine, and the salts thereof include, for example, the above N.
-Acylsarcosine sodium salts, potassium salts, magnesium salts, calcium salts, aluminum salts and the like.

The higher fatty acid ester is a reaction product of a higher fatty acid and an alcohol. When the carbon number of the higher fatty acid is smaller, the higher fatty acid ester of the product is more likely to volatilize, and when the carbon number is larger, the transdermal absorption effect is reduced.
The alcohol has a carbon number of 1 to 20 because the effect of percutaneous absorption decreases as the carbon number of the alcohol increases.

Examples of the higher fatty acid having 10 to 18 carbon atoms include capric acid, lauric acid, myristic acid,
Saturated aliphatic monocarboxylic acids such as palmitic acid and stearic acid; unsaturated aliphatic monocarboxylic acids such as palmitoleic acid, oleic acid, vaccenic acid, linoleic acid, and linolenic acid; and saturated aliphatic dicarboxylic acids such as sebacic acid. Can be

Examples of the alcohol having 1 to 20 carbon atoms include methyl alcohol, ethyl alcohol, propyl alcohol, isopropyl alcohol, butyl alcohol, isobutyl alcohol, tertiary butyl alcohol, pentyl alcohol, hexyl alcohol, heptyl alcohol, octyl alcohol. , Capryl alcohol, nonyl alcohol, decyl alcohol,
Examples include aliphatic saturated alcohols such as lauryl alcohol, myristyl alcohol, palmityl alcohol, and stearyl alcohol.

Examples of the higher fatty acid ester include isopropyl myristate, isopropyl palmitate, isopropyl laurate, isopropyl stearate and the like.

The carbon number of the above dicarboxylic acid (salt) is 2 to 10 because the transdermal absorption effect decreases as the carbon number increases.
As the dicarboxylic acid having 2 to 10 carbon atoms, for example,
Saturated aliphatic dicarboxylic acids such as oxalic acid, malonic acid, succinic acid, glutaric acid, adipic acid, pimelic acid and suberic acid; unsaturated aliphatic dicarboxylic acids such as fumaric acid and maleic acid; phthalic acid, isophthalic acid, terephthalic acid And the salts thereof include, for example, the sodium, potassium, magnesium, calcium, and aluminum salts of the above dicarboxylic acids.

The above-mentioned hydroxycarboxylic acid ester is
It is a reaction product of a hydroxycarboxylic acid and an alcohol. When the carbon number of the hydroxycarboxylic acid is small, the hydroxycarboxylic acid ester of the product is likely to be volatilized, and when it is large, the transdermal absorption effect is deteriorated.
Further, the carbon number of the alcohol is 1 to 20 because the transdermal absorption effect decreases as the alcohol number increases.

Examples of the hydroxycarboxylic acid having 3 to 6 carbon atoms include monocarboxylic acids such as lactic acid and glyceric acid, and dicarboxylic acids such as malic acid and tartaric acid. Examples of the alcohol having 1 to 20 carbon atoms include those similar to those used for the reaction of the higher fatty acid ester. Examples of the hydroxycarboxylic acid esters include myristyl lactate and cetyl lactate.

As the fatty acid ethanolamide, fatty acid monoethanolamide or fatty acid diethanolamide, and alkylene oxide adducts thereof can be used. As the fatty acid ethanolamide,
For example, lauric acid monoethanolamide, lauric acid diethanolamide, lauroyl monoethanolamide, palmitic acid monoethanolamide, palmitic acid diethanolamide, myristic acid monoethanolamide, myristic acid diethanolamide, lauric acid / myristic acid monoethanolamide, coconut Oil fatty acid monoethanolamide, coconut oil fatty acid diethanolamide, polyoxyethylene added lauroyl monoethanolamide, polyoxyethylene added coconut oil fatty acid monoethanolamide and the like can be mentioned.

As the transdermal absorption accelerator, N-lauroyl sarcosine, isopropyl myristate, isopropyl palmitate, fumaric acid, maleic acid, myristyl lactate, cetyl lactate, and diethanolamide laurate are particularly preferable among the above.

As the percutaneous absorption enhancer, the above-mentioned ones are preferable, but not limited thereto, and conventionally known ones can be used.

When the content of the above-mentioned percutaneous absorption enhancer in the external preparation decreases, the effect of promoting percutaneous absorption decreases, and when the content increases, skin irritation is exhibited or fluidity becomes too high, depending on the base. Since it may be difficult to maintain the dosage form,
When the total of the agent for infectious skin diseases, vitamin E, squalane and the base is 100 parts by weight, 0.1 to 25 parts by weight is preferable, and 1 to 12 parts by weight is more preferable.

The dosage forms of the external preparations of the present inventions 1 to 3 are not particularly limited, and include, for example, the above-mentioned drugs (agents for infectious skin diseases, vitamin E and squalane) and percutaneous absorption promotion in the base. What was made into the shape of cream, paste, jelly, gel, emulsion, liquid, etc. by dissolving or mixing and dispersing the agent (used in case of the present invention 3) (ointment, liniment, cream, lotion) Agent, etc.), the above drug and a percutaneous absorption enhancer (used in the case of the present invention 3) dissolved or mixed and dispersed in a base material and spread on a support (such as a poultice), and an adhesive agent. Examples thereof include those obtained by dissolving or mixing and dispersing the above drug and the percutaneous absorption enhancer (used in the case of the present invention 3) on a support (plaster agent, tape agent, etc.) and the like.

As the above-mentioned base, any pharmaceutically acceptable base may be used, including ointments, liniments, creams,
A conventionally known base such as a lotion can be used, for example, sodium alginate, gelatin,
Corn starch, tragacanth, methylcellulose,
Polymers such as hydroxyethyl cellulose, carboxymethyl cellulose, dextrin, carboxymethyl starch, xanthan gum, carrageenan, mannan, agarose, polyvinyl alcohol, sodium polyacrylate, methoxyethylene-maleic anhydride copolymer, polyvinyl ether, polyvinylpyrrolidone; beeswax, olive oil , Cocoa oil, sesame oil, soybean oil, camellia oil, peanut oil, beef oil, pork oil, lanolin and other fats and oils;
White petrolatum, yellow petrolatum; paraffin; hydrocarbon gel (for example, trade name Plastibase, manufactured by Taisho Pharmaceutical Co., Ltd.); higher fatty acids such as stearic acid; higher alcohols such as octyldodecanol and stearyl alcohol; polyethylene glycol (for example, Macrogol 400 ,
Macrogol 4000); glyceryl monostearate; polyoxyethylene cetyl ether; self-emulsifying propylene glycol monostearate; triethanolamine; monooleate ester; glyceride stearate; water and the like.

When the agent for infectious skin diseases is dissolved or mixed and dispersed in the base, the agent for infectious skin diseases may be dissolved in advance in a solvent such as cetyl alcohol before use. .

Further, if necessary, inorganic fillers such as kaolin, bentonite, zinc oxide and titanium oxide; stabilizers such as methyl paraoxybenzoate and propyl paraoxybenzoate; antiaging agents; pH adjusting agents; glycerin and propylene. A moisturizing agent such as glycol may be added.

The above-mentioned support is appropriately selected according to its dosage form (for example, poultice, plaster, tape, etc.), but it is preferable that the drug is impermeable or difficult to permeate and is flexible. Cellulose acetate, ethyl cellulose, polyethylene, polypropylene, polyvinyl chloride, vinyl acetate-vinyl chloride copolymer, ethylene-vinyl acetate copolymer, ethylene-vinyl acetate-carbon monoxide copolymer, ethylene-butyl acrylate-carbon monoxide Resin film such as copolymer, polyvinylidene chloride, polyurethane, nylon, polyethylene terephthalate, polybutylene terephthalate, aluminum sheet, woven cloth, non-woven cloth, etc.,
And a laminated sheet thereof.

The above-mentioned pressure-sensitive adhesive may be any one which is pharmaceutically acceptable, and conventionally known ones can be used. For example, acrylic pressure-sensitive adhesive, rubber pressure-sensitive adhesive, silicone pressure-sensitive adhesive, urethane pressure-sensitive adhesive. Examples thereof include acrylic adhesives and rubber adhesives. When the adhesive is spread on the support, the properties of the adhesive include solvent-based,
Any emulsion type or hot melt type can be used.

Examples of the acrylic pressure-sensitive adhesives include pressure-sensitive adhesives mainly composed of polyalkyl (meth) acrylates obtained by copolymerizing alkyl (meth) acrylates, which are copolymerizable with alkyl (meth) acrylates. It may be a copolymer with a functional monomer or another vinyl monomer.

Examples of the alkyl (meth) acrylate include 2-ethylhexyl (meth) acrylate and dodecyl (meth) acrylate. Examples of the polyfunctional monomer include 1,6-hexane glycol dimethacrylate and tetraethylene glycol diacrylate, and examples of the other vinyl monomer include N-vinyl-2-pyrrolidone and vinyl acetate. Is mentioned.

Examples of the rubber-based pressure-sensitive adhesives include pressure-sensitive adhesives mainly composed of natural rubber, styrene-isoprene-styrene block copolymers, styrene-olefin-styrene block copolymers, etc. Generally, rosin and hydrogenated A tackifier such as rosin, rosin ester, terpene resin, terpene phenol resin, petroleum resin, coumarone resin, coumarone-indene resin is added.

Although the amount of the external preparation for treating infectious skin diseases of the present invention 1 to 3 varies depending on the type of disease, the degree of symptoms, the size of the affected area, etc., the amount of the external preparation is preferably 0 per day. 0.01 to 10 g, which is applied to the affected area once or in appropriate times.

Examples of diseases to be treated by the external preparations for treating infectious skin diseases of the present invention 1 to 3 are, for example, bacterial skin infections; acne vulgaris, pressure ulcers, leg ulcers, radiation ulcers, diabetic gangrene. , Traumatic skin defects, progressive palmar keratoderma, lichen dermatitis, solar dermatitis, liter newborn infant exfoliative dermatitis; in addition to these, contact dermatitis, atopic dermatitis, oil Mention may be made, without limitation, of secondary bacterial infections such as leaky dermatitis, wounds, burns, frostbite and the like.

[0038]

Next, embodiments of the present invention will be described. (Examples 1 to 14 and Comparative Examples 1 to 10) Predetermined amounts (% by weight) of erythromycin (manufactured by Sigma) shown in Tables 1 to 3, tetracycline hydrochloride (manufactured by Sigma), gentamicin sulfate (manufactured by Sigma), Sulfadiazine (manufactured by Sigma), Vitamin E acetate (tocopherol acetate, manufactured by Wako Pure Chemical Industries), Squalane (manufactured by Wako Pure Chemical Industries), Plastibase (manufactured by Taisho Pharmaceutical Co., Ltd.), Macrogol 400
(Manufactured by Wako Pure Chemical Industries, Ltd.), Macrogol 4000 (manufactured by Wako Pure Chemical Industries, Ltd.), cetyl alcohol (manufactured by Wako Pure Chemical Industries, Ltd.), methyl paraoxybenzoate (manufactured by Sigma), propyl paraoxybenzoate (manufactured by Sigma), N. -Lauroyl sarcosine (manufactured by Nacalai Tesque) and isopropyl myristate (manufactured by Nacalai Tesque) were supplied to a mortar and kneaded until the whole became uniform to obtain an ointment.

[0039]

[Table 1]

[0040]

[Table 2]

[0041]

[Table 3]

[Test Example] The following tests were conducted on the ointment obtained above. (Therapeutic effect on rat skin wound suppuration) The back skin of a 6-week-old Wistar rat was shaved with an electric clipper and an electric shaver, and under ether anesthesia with a surgical knife, a length of 30 mm along the back midline. I made a cut. Immediately after making the incision, three places were sewn at equal intervals. 0.2 ml of Staphylococcus aureus adjusted to 1 × 10 ⁵ cfu / ml was added dropwise to this sutured portion to inoculate bacteria. Then, 0.2 g of the ointment obtained in the above Examples and Comparative Examples
Was administered to a range of 2.5 cm × 5 cm including the wound site and left to stand. On the second day from the start of the test, the wound site was observed and judged according to the following criteria. ++: Pus, exudate and erythema are found at the wound site. ++: Although pus is not observed, inflammatory reaction such as erythema and exudate are clearly observed. +: No exudate is observed, but a mild erythema reaction is observed. -: No pus, exudate, erythema, etc.

The test was carried out using 5 rats each, and the number of rats showing the above judgment value was examined, and the results are shown in Table 4.

As a control for this test, the ointments obtained in Examples and Comparative Examples in the above-mentioned test were treated with 0.
Instead of administering 2 g, plastibase or macrogol base (Macrogol 400: Macrogol 40
(00 = 2: 3 mixture), each of which was administered alone in an amount of 0.2 g. In this test result, the judgment value was +++ for all 5 rats in both plastibase and macrogol base.

[0045]

[Table 4]

From Table 4, it can be seen that the external preparation for treating infectious skin diseases of the present invention exhibits a therapeutic effect more than that of the conventional external preparation for treating infectious skin diseases. Vitamin E and squalane by themselves do not have a strong inhibitory effect on infectious pathogens, but since their anti-inflammatory effects are effective together with the effects of agents for infectious skin diseases, they have a high therapeutic effect on infectious skin diseases. Admitted. In particular, the external preparation for treating infectious skin diseases of the present invention markedly suppressed the inflammation of infected skin, as compared with the preparation containing neither vitamin E nor squalane. As described above, the external preparation for the treatment of infectious skin diseases of the present invention was found to be an excellent external preparation for the treatment of infectious skin diseases since it has a strong antibacterial action as well as an anti-inflammatory action.

(Examples 15 to 23 and Comparative Examples 11 to 1)
3) Predetermined amounts (% by weight) of erythromycin (manufactured by Sigma) shown in Tables 5 and 6, tetracycline hydrochloride (manufactured by Sigma), gentamicin sulfate (manufactured by Sigma), vitamin E acetate (tocopherol acetate, pure Wako) Yakusha), squalane (Wako Pure Chemicals), olive oil (Maruishi Pharmaceutical), camellia oil (Maruishi Pharmaceutical), peanut oil (Maruishi Pharmaceutical), soybean oil (Maruishi Pharmaceutical), cetyl Alcohol (manufactured by Wako Pure Chemical Industries, Ltd.), methyl paraoxybenzoate (manufactured by Sigma) and propyl paraoxybenzoate (manufactured by Sigma) are supplied to a beaker and used as a base (olive oil, camellia oil, peanut oil, soybean oil) and others. The mixture was stirred until the additives in Example 1 were uniformly compatible with each other to obtain a liniment agent.

[0048]

[Table 5]

[0049]

[Table 6]

Example 24 [Preparation of Cream] To a reaction Kolben, 100 parts by weight of distilled water and 10.5 parts by weight of propylene glycol are added and heated to 70 ° C. (water phase). Separately, 2 parts by weight of kanamycin sulfate (manufactured by Sigma), 1 part by weight of vitamin E acetate ester (manufactured by Wako Pure Chemical Industries), squalane (manufactured by Wako Pure Chemical Industries) 30
Parts by weight, 4 parts by weight of stearic acid, stearyl alcohol
70 parts by weight of 14 parts by weight, 4 parts by weight of reduced lanolin, 22 parts by weight of octyldodecanol, 10.5 parts by weight of polyoxyethylene cetyl ether, and 7 parts by weight of lipophilic glyceryl monostearate.
Heat to ℃ and mix (oil phase). 89.6 parts by weight of the oil phase is pre-emulsified at 70 ° C. with respect to 100 parts by weight of the water phase. The emulsion was further emulsified with a homomixer and then cooled to room temperature to obtain a cream.

(Example 25) [Preparation of cream] To a reaction Kolben, 100 parts by weight of distilled water and 19.5 parts by weight of propylene glycol are added and heated to 70 ° C (water phase). Separately, 1 part by weight of gentamicin sulfate (manufactured by Sigma), 20 parts by weight of vitamin E acetate ester (manufactured by Wako Pure Chemical Industries), 15 parts by weight of squalane (manufactured by Wako Pure Chemical Industries), 2 parts by weight of beeswax, stearic acid 8 parts by weight, 5 parts by weight of stearyl alcohol, 3.8 parts by weight of self-emulsifying propylene glycol monostearate, 1.2 parts by weight of polyoxyethylene cetyl ether, 4 parts by weight of glycerin, 1 part by weight of triethanolamine are heated to 70 ° C. and mixed. (Oil phase). 104 parts by weight of the oil phase is pre-emulsified at 70 ° C. with respect to 100 parts by weight of the water phase. The emulsion was further emulsified with a homomixer and then cooled to room temperature to obtain a cream.

[0052]

The external preparation for the treatment of infectious skin diseases of the present invention 1 is as described above, and since vitamin E and squalane are added to the agent for infectious skin diseases, the therapeutic effect on the infectious skin diseases is obtained. Is higher than that when the agent for infectious skin diseases is applied alone, and the anti-inflammatory effect is particularly enhanced by the effects of vitamin E and squalane. Therefore, infectious skin diseases are accompanied by inflammation. It is a particularly effective external preparation against.

The external preparation for treating infectious skin diseases of the present invention 2 is as described above, and vitamin E and squalane are added in a specific concentration range to an infectious skin disease agent in a specific concentration range. Since the action of the agent for infectious skin diseases and the anti-inflammatory action of vitamin E and squalane are particularly effective, a higher therapeutic effect can be obtained. Further, the effects of vitamin E and squalane can be expected to have an effect of alleviating local hypersensitivity, irritation, redness, erythema, etc., which are often observed when the agent for infectious skin diseases is applied. Furthermore, it is also an effective external preparation for the complication of infectious diseases in inflammatory skin diseases such as contact dermatitis, atopic dermatitis and seborrheic dermatitis.

The external preparation for infectious skin diseases of the present invention 3 is as described above, and in addition to the agent for infectious skin diseases, vitamin E and squalane, further contains a specific transdermal absorption enhancer. Therefore, the medicinal component is easily absorbed by the infectious pathogen and the skin, and exhibits a higher therapeutic effect on the infectious skin disease.

As described above, the present inventions 1 to 3 solve the problems and provide an external preparation for the treatment of infectious skin diseases, which has a high therapeutic effect. The external preparations for treating infectious skin diseases of the present invention 1 to 3 are contact dermatitis with bacterial infection or secondary infection,
It is particularly effective for atopic dermatitis, seborrheic dermatitis and the like, and since it does not use corticosteroids, it has very few side effects and high safety.

─────────────────────────────────────────────────── ─── Continuation of the front page (51) Int.Cl. ⁶ Identification code Internal reference number FI Technical display area A61K 31/65 ADZ A61K 31/65 ADZ 45/06 45/06 47/12 47/12 E 47 / 14 47/14 E 47/16 47/16 E

Claims (3)

[Claims] 1. An external preparation for treating infectious skin diseases, which comprises an agent for infectious skin diseases, vitamin E and squalane. 2. The content of the agent for infectious skin diseases is 0.01.
-20% by weight, vitamin E content of more than 0.1% by weight and 99.5% by weight or less, and squalane content of 0.1
The external preparation for treating infectious skin diseases according to claim 1, which is more than 9% and less than 99.5% by weight. 3. An N-acyl sarcosine (salt),
Higher fatty acid ester which is a reaction product of higher fatty acid having 10 to 18 carbon atoms and alcohol having 1 to 20 carbon atoms, dicarboxylic acid (salt) having 2 to 10 carbon atoms, hydroxycarboxylic acid having 3 to 6 carbon atoms and carbon The infectious skin disease according to claim 1 or 2, which contains one or more percutaneous absorption enhancers selected from the group consisting of hydroxycarboxylic acid esters, which are reaction products with alcohols of 1 to 20, and fatty acid ethanolamide. External therapeutic agent.